At the time of writing, Zentalis Pharmaceuticals Inc [ZNTL] stock is trading at $11.98, up 3.45%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ZNTL shares have gain 0.04% over the last week, with a monthly amount drifted -4.69%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Zentalis Pharmaceuticals Inc [NASDAQ: ZNTL] stock has seen the most recent analyst activity on November 08, 2023, when Wedbush downgraded its rating to a Neutral and also revised its price target to $12 from $38. Previously, Leerink Partners downgraded its rating to Market Perform on November 07, 2023, and kept the price target unchanged to $15. On July 12, 2022, Cowen initiated with a Outperform rating. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $67 on April 06, 2022. Stifel started tracking with a Buy rating for this stock on September 30, 2021, and assigned it a price target of $84. In a note dated September 29, 2021, Oppenheimer initiated an Outperform rating and provided a target price of $90 on this stock.
For the past year, the stock price of Zentalis Pharmaceuticals Inc fluctuated between $9.56 and $31.46. Currently, Wall Street analysts expect the stock to reach $40.67 within the next 12 months. Zentalis Pharmaceuticals Inc [NASDAQ: ZNTL] shares were valued at $11.98 at the most recent close of the market. An investor can expect a potential return of 239.48% based on the average ZNTL price forecast.
Analyzing the ZNTL fundamentals
Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -6.08%, Pretax Profit Margin comes in at -4.83%, and Net Profit Margin reading is -5.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -0.46 and Total Capital is -0.52. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.55 points at the first support level, and at 11.12 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.21, and for the 2nd resistance point, it is at 12.44.
Ratios To Look Out For
It is important to note that Zentalis Pharmaceuticals Inc [NASDAQ:ZNTL] has a current ratio of 9.19. In addition, the Quick Ratio stands at 9.19 and the Cash Ratio stands at 0.69. Considering the valuation of this stock, the price to sales ratio is 20.97, the price to book ratio is 1.85.
Transactions by insiders
Recent insider trading involved HAUSMAN DIANA, Chief Medical Officer, that happened on May 09 ’24 when 3356.0 shares were sold. Chief Financial Officer, Epperly Melissa B, completed a deal on Feb 12 ’24 to sell 2573.0 shares. Meanwhile, President Gallagher Cam sold 1173.0 shares on Feb 12 ’24.
